Supernus Pharmaceuticals annual operating income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Operating Income Growth & History (SUPN)
Supernus Pharmaceuticals's operating income was −$62.3M for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$62.3M | −$143.9M | — |
| 2024 | 2024-12-31 | $81.7M | $86.9M | — |
| 2023 | 2023-12-31 | −$5.3M | −$51.4M | — |
| 2022 | 2022-12-31 | $46.1M | −$39.9M | −46.39% |
| 2021 | 2021-12-31 | $86.0M | −$87.7M | −50.47% |
| 2020 | 2020-12-31 | $173.7M | $25.1M | +16.91% |
| 2019 | 2019-12-31 | $148.6M | $4.1M | +2.86% |
| 2018 | 2018-12-31 | $144.4M | $44.9M | +45.11% |
| 2017 | 2017-12-31 | $99.5M | $45.3M | +83.60% |
| 2016 | 2016-12-31 | $54.2M | $33.4M | +160.10% |
| 2015 | 2015-12-31 | $20.8M | $26.1M | — |
| 2014 | 2014-12-31 | −$5.3M | $56.6M | — |
| 2013 | 2013-12-31 | −$61.9M | −$19.8M | — |
| 2012 | 2012-12-31 | −$42.2M | −$4.4M | — |
| 2011 | 2011-12-31 | −$37.8M | $2.4M | — |
| 2010 | 2010-12-31 | −$40.1M | — | — |
Supernus Pharmaceuticals quarterly operating income
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$58.0M | −$70.1M | — |
| Q1 2026 | 2026-03-31 | −$8.3M | $1.9M | — |
| Q4 2025 | 2025-12-31 | −$3.9M | −$25.3M | — |
| Q3 2025 | 2025-09-30 | −$60.2M | −$101.1M | — |
| Q2 2025 | 2025-06-30 | $12.1M | −$10.4M | −46.20% |
| Q1 2025 | 2025-03-31 | −$10.3M | −$7.1M | — |
| Q4 2024 | 2024-12-31 | $21.4M | $22.4M | — |
| Q3 2024 | 2024-09-30 | $40.8M | $32.7M | +401.90% |
| Q2 2024 | 2024-06-30 | $22.6M | $40.2M | — |
| Q1 2024 | 2024-03-31 | −$3.2M | −$8.3M | — |
| Q4 2023 | 2023-12-31 | −$996,000 | −$35.3M | — |
| Q3 2023 | 2023-09-30 | $8.1M | $9.7M | — |
| Q2 2023 | 2023-06-30 | −$17.6M | −$28.9M | — |
| Q1 2023 | 2023-03-31 | $5.2M | $3.2M | +163.14% |
| Q4 2022 | 2022-12-31 | $34.3M | $28.2M | +463.04% |
| Q3 2022 | 2022-09-30 | −$1.5M | −$34.1M | — |
| Q2 2022 | 2022-06-30 | $11.3M | −$22.8M | −66.74% |
| Q1 2022 | 2022-03-31 | $2.0M | −$11.2M | −85.11% |
| Q4 2021 | 2021-12-31 | $6.1M | −$36.9M | −85.82% |
| Q3 2021 | 2021-09-30 | $32.6M | −$23.5M | −41.92% |
| Q2 2021 | 2021-06-30 | $34.1M | −$11.4M | −25.11% |
| Q1 2021 | 2021-03-31 | $13.2M | −$15.8M | −54.45% |
| Q4 2020 | 2020-12-31 | $43.0M | $2.2M | +5.35% |
| Q3 2020 | 2020-09-30 | $56.1M | $16.4M | +41.31% |
| Q2 2020 | 2020-06-30 | $45.5M | $3.0M | +6.93% |
| Q1 2020 | 2020-03-31 | $29.0M | $3.6M | +14.09% |
| Q4 2019 | 2019-12-31 | $40.8M | $961,000 | +2.41% |
| Q3 2019 | 2019-09-30 | $39.7M | $2.3M | +6.01% |
| Q2 2019 | 2019-06-30 | $42.6M | $6.9M | +19.26% |
| Q1 2019 | 2019-03-31 | $25.4M | −$6.0M | −19.00% |
| Q4 2018 | 2018-12-31 | $39.9M | $5.5M | +16.05% |
| Q3 2018 | 2018-09-30 | $37.5M | $15.1M | +67.73% |
| Q2 2018 | 2018-06-30 | $35.7M | $9.7M | +37.03% |
| Q1 2018 | 2018-03-31 | $31.4M | $14.6M | +87.00% |
| Q4 2017 | 2017-12-31 | $34.3M | $18.0M | +110.75% |
| Q3 2017 | 2017-09-30 | $22.3M | $2.5M | +12.62% |
| Q2 2017 | 2017-06-30 | $26.1M | $14.4M | +123.85% |
| Q1 2017 | 2017-03-31 | $16.8M | $10.4M | +160.80% |
| Q4 2016 | 2016-12-31 | $16.3M | $8.4M | +106.78% |
| Q3 2016 | 2016-09-30 | $19.8M | $14.8M | +290.15% |
| Q2 2016 | 2016-06-30 | $11.6M | $7.8M | +202.94% |
| Q1 2016 | 2016-03-31 | $6.4M | $2.4M | +59.57% |
| Q4 2015 | 2015-12-31 | $7.9M | $2.8M | +53.81% |
| Q3 2015 | 2015-09-30 | $5.1M | $5.8M | — |
| Q2 2015 | 2015-06-30 | $3.8M | $88,000 | +2.34% |
| Q1 2015 | 2015-03-31 | $4.0M | $17.5M | — |
| Q4 2014 | 2014-12-31 | $5.1M | $16.5M | — |
| Q3 2014 | 2014-09-30 | −$736,000 | $16.4M | — |
| Q2 2014 | 2014-06-30 | $3.8M | $19.2M | — |
| Q1 2014 | 2014-03-31 | −$13.4M | $4.5M | — |
| Q4 2013 | 2013-12-31 | −$11.4M | $1.4M | — |
| Q3 2013 | 2013-09-30 | −$17.2M | −$4.9M | — |
| Q2 2013 | 2013-06-30 | −$15.5M | −$6.2M | — |
| Q1 2013 | 2013-03-31 | −$17.9M | −$10.0M | — |
| Q4 2012 | 2012-12-31 | −$12.7M | −$2.5M | — |
| Q3 2012 | 2012-09-30 | −$12.3M | −$2.4M | — |
| Q2 2012 | 2012-06-30 | −$9.3M | −$861,000 | — |
| Q1 2012 | 2012-03-31 | −$7.9M | $1.3M | — |
| Q4 2011 | 2011-12-31 | −$10.2M | — | — |
| Q3 2011 | 2011-09-30 | −$9.9M | — | — |
| Q2 2011 | 2011-06-30 | −$8.4M | — | — |
| Q1 2011 | 2011-03-31 | −$9.2M | — | — |
Supernus Pharmaceuticals operating income trends
Over the last five fiscal years, Supernus Pharmaceuticals's operating income decreased from $173.7M to −$62.3M, a change of −$236.0M. The latest reported quarter, Q2 2026, shows −$58.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
